Hypertension is considered a major health problem around the world. It’s associated with increasing risk of mortality due to its complication which has a great impact on patient’s life quality.

Chronic uncontrolled hypertension is a significant risk factor for cardiovascular mortality and morbidity, strokes, heart failure, and renal failure.

The European Society of Cardiology recommends initial combination therapy for the majority of patients with HTN. The European Society recommends starting a low-dose combination therapy before single-dose therapy of hypertension.

More than two-thirds of patients with hypertension require treatment with two or more antihypertensive drugs to achieve their target BP goals.

TAKE HOME MESSAGE:

The aims of this study were to evaluate the 24-h antihypertensive efficacy of T40/A5 FDC therapy and to explore differences that may arise owing to different administration times in Japanese patients whose hypertension was not controlled by 5 mg of amlodipine per day.

Telmisartan and amlodipine, including all doses, provides superior BP reduction than other antihypertensive agents alone and demonstrates 24-hour BP control.

Fixed-dose combination (FDC) therapy with telmisartan 40 mg + amlodipine 5 mg (T40/A5) is expected to achieve tight blood pressure (BP) control because of the strong efficacy and long half-life of each drug.

Authors conclude that T40/A5 FDC therapy significantly decreased the 24-h mean and clinical BP, independent of administration time, in patients whose hypertension was not controlled by 5 mg of amlodipine.

Telmisartan plus amlodipine can be a reasonable choice for hypertensive patients who likely will require more than one agent for BP control.